PECAM1 and acute myeloid leukemia: After 3 weeks treatment, we observed reduced CD31+Sca-1high ECs and arterioles (Additional file 1: Fig. S13a–d), a significant reduction of leukemia burden and LSCs, reduced miR-126 levels in AML LSCs (Fig. 6g) likely due to reduced EC supply, and increased survival (Fig. 6h; left) in the AC220-treated miR-126ECΔ/Δ primary mice compared with the AC220-treated miR-126ECwt/wt controls.